TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients

Peer Review reports

Original Submission
30 Aug 2011	Submitted	Original manuscript
3 Oct 2011	Reviewed	Reviewer Report - M. Idrees
19 Oct 2011	Reviewed	Reviewer Report - Saumitra Das
17 Dec 2011	Author responded	Author comments - Hans Dieter Nischalke
Resubmission - Version 2
17 Dec 2011	Submitted	Manuscript version 2
Publishing
8 Mar 2012	Editorially accepted
8 Mar 2012	Article published	10.1186/1471-2407-12-85

Back to article page